Robert W. Duggan - Chief Executive Officer
Chief Executive Officer and Chairman of the Board of Directors of Pharmacyclics, Mr. Duggan has been a member of the Board of Directors since September 2007. He served as Chairman of the Board of Directors of Computer Motion, Inc., a computerized surgical systems company, from 1990 to 2003 and Chief Executive Officer from 1997. Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. Mr. Duggan is the Founder of the investment firm Robert W. Duggan & Associates. Mr. Duggan has been a private venture investor for more than 30 years and has participated as a director of, investor in and advisor to numerous small and large businesses in the medical equipment, computer local and wide area network, PC hardware and software distribution, digital encryption, consumer retail goods and outdoor media communication industries. Mr. Duggan has also assisted in corporate planning, capital formation and management for his various investments. He received the Congressman’s Medal of Merit and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac. Mr. Duggan is currently also a director of Intuitive Surgical, Inc. He is a member of the University of California at Santa Barbara Foundation Board of Trustees.
David Loury, Ph.D. - Chief Scientific Officer
David Loury joined Pharmacyclics as Vice President, Preclinical Sciences in May 2006 with 20 years of pharmaceutical industry experience. Most recently Dr. Loury served at Celera Genomics as Senior Director of Toxicology from April 2003 to April 2006. Prior to that, Dr Loury directed Drug Disposition, and Toxicology at Essential Therapeutics and IntraBiotics Pharmaceuticals from January 1996 to May 2001. Dr. Loury has held positions of increasing responsibility in Preclinical Safety at Syntex Corporation and Roche Pharmaceuticals. He is a Diplomate of the American Board of Toxicology. Dr. Loury received a B.S. degree in Environmental Toxicology and a Ph.D. in Pharmacology and Toxicology from the University of California, Davis.
Ahmed Hamdy, MD - Chief Medical Officer
Dr. Hamdy most recently served as Therapeutic Area Head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical development. Dr Hamdy's experience ranges across all clinical development phases. He has a track record of delivering a number of INDs and NDAs . In the past, Dr Hamdy was responsible for multiple clinical trials where he authored and oversaw the development of multiple clinical development plans, protocols and study reports in numerous therapeutic areas (oncology, urology, autoimmune, anemia, pain and cardiovascular).Dr. Hamdy has also served as the General Medicine Therapeutic Area Head at PDL BioPharma from February 2006 to June 2008, where he was responsible for the clinical development activities for Cardene IV(r) premixed bag formulations, which was approved in 2008 and the development of Ularitide(r) for the treatment of congestive heart failure. From September 2004 to February 2006, Dr. Hamdy was a medical director at Johnson and Johnson/ALZA where he participated in NDA submissions for OROS Hydromorphone (Jurnista(r)) for moderate to severe pain approved in Europe 2006. From October 2000 to August 2004, Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals where he participated in an ANDA for testosterone gel for the treatment of hypogonadism that was approved 2005. He also participated in multiple INDs in oncology and autoimmune diseases leading to successful phase I and phase II programs. Dr Hamdy received his M.D. (M.B.B.Ch) from Cairo University, Egypt.
Maky Zanganeh, D.D.S. - Vice President, Business Development and Marketing
Maky Zanganeh joined Pharmacyclics as Vice President, Business Development and Marketing in August 2008. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert Duggan & Associates. While working with Mr. Duggan, she accepted a position as Director General (2007-2008) for the French government initiative biocluster project in France. Prior to joining Duggan & Associates, Dr. Zanganeh was worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle east and Africa (1998 - 2002) for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France. She is fluent in French, German, Persian & English.
Rainer (Ramses) Erdtmann, Vice President, Finance & Administration
Mr. Erdtmann began his career in Europe as an investment banker. He was accepted into the Investment Banking Program of Commerzbank in Germany after he graduated with distinction from the Westfaelische Wilhelms Universitaet in Muenster, majoring in Financing and Banking. He was later recruited by the asset management arm of Commerzbank and became a portfolio manager for international clients. The portfolio assets under management exceeded $1Billion Dollars. In 1994 he co- founded a German-based real estate company, United Properties Immobilien & Anlagen GmbH, which to date has successfully developed over 30 different projects and manages a portfolio of over 250 units. His main area of responsibility has been setting up the organization and overseeing the financial aspects of its operations. Mr. Erdtmann came to the US in the mid- nineties to manage the assets for a US equity pool and several European investors. He became actively involved in some of the holding companies and served on several of their boards. Building on his European network, he has since consulted high net-worth individuals and closed-end funds, and actively advised in the selection of US investments for over $500 Million. Furthermore he finalized over $120 Million of equity and debt transactions for private equity partnerships.
Gregory Hemmi, Ph.D. - Vice President, Chemical Operations
Gregory Hemmi has served as Vice President, Chemical Operations since May 2006. Dr. Hemmi served as Senior Director, Chemical Development from January 2001 to April 2006 and as Director, Chemical Development from December 1997 to December 2000. Other positions held at Pharmacyclics include Group Leader, Chemical Development from May 1995 to November 1997 and Scientist from June 1992 to April 1995. After graduating with a B.S. in Chemistry, Dr. Hemmi received a Ph.D. from the University of Texas at Austin under the direction of Professor Jonathan L. Sessler.
Joseph J. Buggy, Ph.D. - Vice President, Research
Joseph J. Buggy has served as Vice President, Research since September 2007. From May 2006 to August 2007, Dr. Buggy served as Senior Director, Cancer Biology. From November 2001 to April 2006, he served as Director, Department of Biology at Celera Genomics, a biotechnology company. From June 1996 to October 2001, he was a staff scientist at AXYS Pharmaceuticals, Inc., a biotechnology company. Prior to that Dr. Buggy worked as a scientist at Bayer Corporation in West Haven, CT. Dr. Buggy received a Ph.D. in Molecular, Cellular, and Developmental Biology from Indiana University and a B.S. degree in Microbiology from the University of Pittsburgh.